Ziccum AB (publ) (ZICC.ST)
SEK 0.25
(0.0%)
SEK 0.25
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 6.38 Million SEK | 60.34% |
| 2022 | 3.98 Million SEK | -44.43% |
| 2021 | 7.16 Million SEK | 119.98% |
| 2020 | 3.25 Million SEK | 165.17% |
| 2019 | 1.22 Million SEK | 55.57% |
| 2018 | 790 Thousand SEK | 2533.33% |
| 2017 | 30 Thousand SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 7.18 Million SEK | 12.54% |
| 2024 Q3 | 7.32 Million SEK | -3.91% |
| 2024 Q2 | 7.62 Million SEK | 6.06% |
| 2023 FY | 6.38 Million SEK | 60.34% |
| 2023 Q1 | 4.36 Million SEK | 9.61% |
| 2023 Q3 | 5.86 Million SEK | 18.42% |
| 2023 Q2 | 4.95 Million SEK | 13.4% |
| 2023 Q4 | 6.38 Million SEK | 8.94% |
| 2022 Q4 | 3.98 Million SEK | -26.0% |
| 2022 Q2 | 7.39 Million SEK | 8.26% |
| 2022 FY | 3.98 Million SEK | -44.43% |
| 2022 Q1 | 6.83 Million SEK | -4.71% |
| 2022 Q3 | 5.38 Million SEK | -27.19% |
| 2021 Q2 | 4.5 Million SEK | 20.21% |
| 2021 FY | 7.16 Million SEK | 119.98% |
| 2021 Q3 | 5.2 Million SEK | 15.55% |
| 2021 Q1 | 3.75 Million SEK | 15.07% |
| 2021 Q4 | 7.16 Million SEK | 37.63% |
| 2020 Q3 | 3.08 Million SEK | -29.21% |
| 2020 Q2 | 4.35 Million SEK | 255.76% |
| 2020 Q1 | 1.22 Million SEK | -0.33% |
| 2020 FY | 3.25 Million SEK | 165.17% |
| 2020 Q4 | 3.25 Million SEK | 5.64% |
| 2019 Q4 | 1.22 Million SEK | 94.46% |
| 2019 Q3 | 632 Thousand SEK | -38.22% |
| 2019 Q2 | 1.02 Million SEK | 28.68% |
| 2019 FY | 1.22 Million SEK | 55.57% |
| 2019 Q1 | 795 Thousand SEK | 0.63% |
| 2018 FY | 790 Thousand SEK | 2533.33% |
| 2018 Q4 | 790 Thousand SEK | 0.0% |
| 2018 Q1 | - SEK | -100.0% |
| 2018 Q2 | 2.84 Million SEK | 0.0% |
| 2017 Q4 | 30 Thousand SEK | 0.0% |
| 2017 FY | 30 Thousand SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alzinova AB (publ) | 9.33 Million SEK | 31.54% |
| Amniotics AB (publ) | 10.54 Million SEK | 39.433% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -44.329% |
| BioArctic AB (publ) | 139.5 Million SEK | 95.421% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 99.592% |
| Genovis AB (publ.) | 98.04 Million SEK | 93.485% |
| LIDDS AB (publ) | 3.75 Million SEK | -70.075% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 94.848% |
| OncoZenge AB (publ) | 1.69 Million SEK | -275.986% |
| Saniona AB (publ) | 86.08 Million SEK | 92.579% |
| Simris Alg AB (publ) | 148.93 Million SEK | 95.711% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 84.366% |
| AcouSort AB (publ) | 10.37 Million SEK | 38.447% |
| Active Biotech AB (publ) | 13.4 Million SEK | 52.328% |
| Camurus AB (publ) | 414.81 Million SEK | 98.46% |
| Cantargia AB (publ) | 54.97 Million SEK | 88.379% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -66.441% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | 65.459% |
| Mendus AB (publ) | 51.22 Million SEK | 87.53% |
| Kancera AB (publ) | 17.97 Million SEK | 64.468% |
| Karolinska Development AB (publ) | 11.56 Million SEK | 44.783% |
| Lipum AB (publ) | 7.53 Million SEK | 15.256% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -23.846% |
| NextCell Pharma AB | 13.68 Million SEK | 53.335% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 98.675% |
| Xintela AB (publ) | 14.01 Million SEK | 54.42% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | 53.615% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -170.793% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 66.667% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 91.109% |
| CombiGene AB (publ) | 4.15 Million SEK | -53.706% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 91.018% |
| Intervacc AB (publ) | 21.68 Million SEK | 70.535% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 94.007% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 81.539% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 76.082% |
| Corline Biomedical AB | 6.78 Million SEK | 5.907% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 89.589% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | 60.365% |
| Aptahem AB (publ) | 8.99 Million SEK | 29.005% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 86.167% |
| Fluicell AB (publ) | 8.91 Million SEK | 28.345% |
| Biovica International AB (publ) | 34.76 Million SEK | 81.626% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | 45.252% |
| Abliva AB (publ) | 16.78 Million SEK | 61.933% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 97.023% |
| 2cureX AB (publ) | 2.93 Million SEK | -117.649% |
| I-Tech AB | 16.2 Million SEK | 60.58% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 99.461% |
| Cyxone AB (publ) | 4.69 Million SEK | -36.089% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | 52.071% |
| Biosergen AB | 5.08 Million SEK | -25.624% |
| Nanologica AB (publ) | 79.32 Million SEK | 91.947% |
| SynAct Pharma AB | 51.83 Million SEK | 87.676% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | 19.638% |
| BioInvent International AB (publ) | 90.45 Million SEK | 92.938% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -22.966% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 96.482% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -256.076% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | 49.874% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | 12.011% |